Get Even More Visitors To Your Blog, Upgrade To A Business Listing >>

USFDA’s notice may shave off 2-6% from Sun Pharma’s EPS in FY18

Analyst believes that Form 483 observations may delay the clearance of Halol facility and see full remediation only by first quarter of calendar year 2018. Via:: Economic Times India



This post first appeared on My Finance Reporter | Australian, Asian & US Finan, please read the originial post: here

Share the post

USFDA’s notice may shave off 2-6% from Sun Pharma’s EPS in FY18

×

Subscribe to My Finance Reporter | Australian, Asian & Us Finan

Get updates delivered right to your inbox!

Thank you for your subscription

×